Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs.

ABSTRACT:

Background

This study aimed to describe the clinical and cost-effectiveness evidence supporting reimbursement decisions of new cancer drugs and analyze the influence of trial characteristics and the cost per quality-adjusted life years (QALYs) on the likelihood of reimbursement in Sweden.

Patients and methods

Data were extracted from all appraisal dossiers for new cancer drugs seeking reimbursement in Sweden and claiming added therapeutical value between the years 2010 and 2020. The data were analyzed using descriptive statistics, and logistic regression models were also used with the cost per QALY, study design, comparator, and evidence on final outcomes in the clinical trials as predictors of reimbursement.

Results

All 60 included appraisals were based on trial evid

SUBMITTER: Chauca Strand G 

PROVIDER: S-EPMC9588887 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature